You are here:

International Course on the Clinical and Programmatic Management of Drug-Resistant Tuberculosis 2024

Published on


14-18 October 2024

In-person course.

Union TATA and Wanfang Hospital logos

This course is being organized by The Union in partnership with Wan Fang Hospital, Taipei Medical University and Taiwan Anti-Tuberculosis Association.

The International Course on the Clinical and Programmatic Management of Drug-Resistant Tuberculosis is a five-day in-person course that will take place in Taipei (Taiwan) from the 14th to th 18th October 2024. The course aims to strengthen participants’ capacity in the clinical and programmatic management of drug-resistant tuberculosis.

There are optional online course materials, which include on-demand videos and quizzes. They are recommended as preparation for the in-person session.

The 2024 edition of the course includes guests speakers to present the latest WHO guidelines as well as considerations about implementation in limited-resource settings and latest research findings. Participants will visit the Taiwan Centers for Disease Control.

Course Objectives

At the end of this course, participants will be able to:

  • Describe the current global epidemiological situation of drug-resistant tuberculosis
  • Describe the different approaches for the detection and diagnosis of drug-resistant tuberculosis
  • Address the principles of  treatment and regimen design, according to different patterns of drug-resistance
  • Review key second line and new anti-tuberculosis medicines
  • Discuss common problems and possible solutions for programmatic management of drug-resistant tuberculosis

Course Brief

Who Should Attend

This course is designed for clinicians, who are responsible for diagnosis and treatment of drug-resistant tuberculosis, staff of national tuberculosis programmes and technical partners, working in tuberculosis care and prevention, in low- and middle-income countries, especially in settings where programmatic management of drug-resistant tuberculosis (PMDT) had been or is going to be implemented. Please note this is a specialist course.

Course Fee: 2,000 EUR This price is subsidized thanks to the in-kind contributions of the Wan Fang Hospital, Taipei Medical University and Taiwan Anti-Tuberculosis Association. The fee is payable via credit card or international bank transfer.

The course fee includes:

  • Unlimited access to the online course materials
  • Five-day in-person sessions Taipei
  • Lunch and coffee breaks during the in-person session

The fee does not include accommodation, visa or transport costs.

Course Faculty

  • Scientific Committee: Dr Chen-Yuan Chiang (Course Director), Dr Rebecca Lin and Dr Ignacio Monedero
  • Guest speakers include representatives from the Wan Fang Hospital, Taiwan Anti-Tuberculosis Association, the Taiwan Centers for Disease Control and the World Health Organization (names to be confirmed).

As per individual signed conflict of interest declarations, the members of the Scientific Committee and faculty do not have perceived or actual conflicts of interest to deliver the content of the course.

Faculty bios

Language: English


From the 14th to the 18th October 2024 in Taipei (Taiwan).

Please plan to arrive to Taipei on the 13th and leave on the 19th October.


To complete your registration, you will need to submit a CV and the details of your sponsor or the person paying for the course fees, so we can issue an invoice. Because this is a specialist course, the Course Director will review registration requests so please include your medical titles and experience in the clinical and/or programmatic management of DR-TB.

Registration will close on the 15th September 2024 or when we reach 25 participants (whichever comes first).


This year, The Union has secured external funding and is able to waive the course fees to some participants from high MDR-TB burden countries associated to a National TB Programme.

To request a scholarship, complete a registration form and when asked for the sponsor, select the “scholarship” option. You will need to submit a CV and a letter of support or evidence that you have funding to cover your travel and accommodation to attend the course.

Please note the number of requests for scholarship received exceeded the number of scholarships available, so the scholarships have been be allocated according to the eligible criteria: clinician working on the clinical or programmatic management of DRTB in a high MDRTB burden country, associated with a national TB programme, with sufficient funds to cover transport and accommodation. The scholarships have already been allocated. If a scholarship is not accepted by the end of July, we will offer it to the next eligible person on the list. All scholarships will be allocated by end of August to allow time for participants to organise their travel, accommodation and visa process.